VANCOUVER, British Columbia, Oct. 11, 2018 — Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that its CEO Dr. Lui Franciosi and Medical Director Dr. Scott Alexander will be attending the 3rd International Medical Cannabis Conference, or (“CannX”) in Tel Aviv, Israel from October 14 to 16, 2018.
CannX is a meeting of global leaders in all areas of medical cannabis where the latest scientific and clinical research, agricultural practices, innovation, and business opportunities are explored. Dr. Raphael Mechoulam, Professor of Medicinal Chemistry at the Hebrew University of Jerusalem, will be chairing this conference. He was the first person to isolate, elucidate and synthesize Δ9-tetrahydrocannabinol (THC), the active principal of cannabis, and provided a great understanding of the chemicals that form the basis of the body’s cannabinoid system. Israel has been one of the world’s leading countries for medical cannabis research. It has numerous academic organizations as well as companies that have conducted extensive scientific research in the development of efficacious, data-driven cannabis treatments to help patients.
Veritas CEO, Dr. Lui Franciosi stated that “Our time in Israel will enable us to get a better sense of latest preclinical and clinical research being conducted in both academia and industry. Dr. Alexander and I are also interested in learning more at the Conference about their recent research demonstrating the safe and effective use of cannabis in the elderly and the related reduction in prescription drug use, including opioids, in this population.”
Eyal Mishori, the Co-founder & CEO of IsCann Group, will also be in attendance. He has organized a number of meetings for Veritas with leading Israeli scientists, clinicians, biotech firms, and investors to further the Company’s understanding of medical cannabis, establish potential new research collaborations, as well as investigate potential licensing opportunities for acquiring select products for specific patient populations in Canada.
About Veritas Pharma Inc. Veritas Pharma Inc. is an emerging pharmaceutical and IP development company, who, through its 100% owned subsidiary Cannevert Therapeutics Ltd. (“CTL“), is advancing the science behind medical cannabis. It is the Company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas’ investment in CTL is led by a strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion-dollar markets according to Deloitte’s Insights and Opportunities.
Veritas Pharma Inc. is a publicly traded company in Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.
For more information, please visit our website: veritaspharmainc.com
On behalf of the Board of Directors
“Dr. Lui Franciosi” Dr. Lui Franciosi President and Chief Executive Officer
Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.
Investor and Public Relations Contact Veritas Pharma Inc. Jamie Hyland Telephone: +1.416.918.6785 Email: [email protected] Website: www.veritaspharmainc.com
The CSE has not reviewed, nor approved or disapproved the content of this press release.